254 related articles for article (PubMed ID: 19460715)
41. [Herceptin plus adjuvant chemotherapy for the prognosis of patients with human epithelial growth factor receptor 2 positive early-stage breast cancer: a meta-analysis].
Wu F; Hu CH; Jiang SA; Lu FG; Lin MH; Deng XG
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):684-9. PubMed ID: 17767066
[TBL] [Abstract][Full Text] [Related]
42. Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial.
Yamaguchi T; Mukai H
Jpn J Clin Oncol; 2012 Dec; 42(12):1211-4. PubMed ID: 23129778
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
[TBL] [Abstract][Full Text] [Related]
44. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
[TBL] [Abstract][Full Text] [Related]
45. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA
J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916
[TBL] [Abstract][Full Text] [Related]
46. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
47. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E; Carbognin L; Furlanetto J; Pilotto S; Bonomi M; Guarneri V; Vicentini C; Brunelli M; Nortilli R; Pellini F; Sperduti I; Giannarelli D; Pollini GP; Conte P; Tortora G
Cancer Treat Rev; 2014 Aug; 40(7):847-56. PubMed ID: 24877987
[TBL] [Abstract][Full Text] [Related]
48. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.
Lazaridis G; Pentheroudakis G; Pavlidis N
Crit Rev Oncol Hematol; 2008 Apr; 66(1):31-41. PubMed ID: 17766143
[TBL] [Abstract][Full Text] [Related]
49. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
Wang LP; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
[No Abstract] [Full Text] [Related]
50. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
Wang Y; Liu Y; Du Y; Yin W; Lu J
Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
[TBL] [Abstract][Full Text] [Related]
51. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
52. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
Baena-Canada JM; Estalella S; Rosado P
Cancer; 2011 Apr; 117(8):1783; author reply 1783-4. PubMed ID: 21472726
[No Abstract] [Full Text] [Related]
53. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
54. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
55. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Zhu ZL; Zhang J; Chen ML; Li K
Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
[TBL] [Abstract][Full Text] [Related]
56. The HER2 World: Better Treatment Selection for Better Outcome.
Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S
J Natl Cancer Inst Monogr; 2011; 2011(43):82-5. PubMed ID: 22043048
[TBL] [Abstract][Full Text] [Related]
57. What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?
Gourmelon C; Frenel JS; Campone M
Expert Rev Anticancer Ther; 2012 Feb; 12(2):195-201. PubMed ID: 22316367
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
[TBL] [Abstract][Full Text] [Related]
59. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Del Mastro L; Bighin C; Bini G; Giraudi S; Taveggia P; Levaggi A; Canavese G; Rescinito G; Pronzato P
Ann Oncol; 2010 Jun; 21(6):1376-1377. PubMed ID: 20430904
[No Abstract] [Full Text] [Related]
60. [Trastuzumab for treatment of advanced breast cancers].
Watanabe T; Shimizu C; Katsumata N; Saijo N
Nihon Rinsho; 2000 Apr; 58 Suppl():340-4. PubMed ID: 11026016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
